How US FDA's Assumptions Impacted Generic Program Fees

FDA decided against trying to predict upcoming approvals as part of FY 2019 GDUFA program fee calculations, but other adjustments likely increased fee significantly.

FDAEntrance_1200x675

More from US FDA

More from Agency Leadership